A variety of policy proposals have been put forward to help spur the US uptake of biosimilars, from legislative solutions to regulatory changes, but some providers are taking the matter into their own hands with concerted efforts to bring biosimilars to the clinic.
Biosimilars have struggled to gain ground in the United States, with few products launched, relatively low uptake of commercially available products, formulary restrictions that sometimes favor branded biologics over biosimilar options, and exclusionary contracting practices that block biosimilars from formularies altogether.
A variety of policy proposals have been put forward to help spur the US uptake of biosimilars, from legislative solutions to regulatory changes, but some providers are taking the matter into their own hands with concerted efforts to bring biosimilars to the clinic.
In an editorial appearing at the Articularis Health Group’s (AHG) website, Colin C. Edgerton, MD, one of the founding members of the rheumatology practice, explained that AHG has created a value-based rheumatoid arthritis (RA) treatment pathway that has boosted biosimilar use.
Using the American College of Rheumatology’s 2015 guidelines, the organization developed its value-based pathway with the goals of reducing costs for RA treatment while improving quality of care and patient outcomes. Edgerton explains that AHG collaborated with its largest commercial payer to model the pathway, then integrated the payer-approved pathway into its NexGen electronic health record (EHR) system in partnership with TSI Healthcare.
According to a June 2019 statement, TSI developed the logic of the integrated EHR tool to ensure that it did not impede providers’ workflow or create any new, unnecessary clicks; the tool supports rheumatologists’ adherence to the RA pathway’s evidence-based guidelines, thereby reducing the cost of care while maintaining physician’s autonomy.
As part of implementing the pathway and working with the payer team, Edgerton explains, the organization was able to negotiate biosimilars as first-line treatment for RA, overcoming a previous restriction from the payer’s formulary. “Our physicians may now prescribe the infliximab biosimilars Inflectra and Renflexis, or the originator Remicade, as first-line biologic therapy without the need for prior authorization. Indeed, the pathway program has eliminated prior authorization for any biologic agent,” writes Edgerton.
Biosimilars, he adds, are a “win-win for the practice, payers, and patient access,” and part of a shift toward biosimilar use at AHG has the result of holding meetings to review cost and utilization data for each prescriber. Many rheumatologists, he notes, were unaware that subcutaneous biologics result in higher spending than intravenously administered biosimilars, and prescribing habits have shifted toward biosimilars on the basis of better understanding of these costs.
Practice size has been a key factor in the success of the RA pathway, he writes, adding that rheumatologists may be constrained in their move to value-based pathways by their often small practice sizes. To help mitigate those constraints, AHG has launched the Articularis Rheumatology Network, which offers a group purchasing organization to allow members to purchase medications at discounts, and which offers the use of the value-based RA pathway program at zero cost.
Physician and Patient Perspectives After Starting or Switching to Amgevita in IBD
March 23rd 2024A real-world study surveying physicians and patients on adalimumab biosimilar ABP 501 (Amgevita) in inflammatory bowel disease (IBD) found both patients initiating ABP 501 and those who had switched from the reference product had higher satisfaction levels.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Webinar Addresses Solutions to Improve Adalimumab Biosimilar Uptake
March 18th 2024Government policies, including those related to prescribing incentives and interchangeability, need to be reworked to encourage biosimilar adoption and create meaningful savings for health systems, according to speakers at a recent webinar.
Biosimilars Rheumatology Roundup for February 2024—Podcast Edition
March 3rd 2024On this episode of Not So Different, The Center for Biosimilars® revisited all the major rheumatology biosimilar news from February 2024, including the FDA approval of the 10th adalimumab biosimilar, the promise for an oral delivery system for ustekinumab, and the impact of adalimumab products on COVID-19 antibodies.
The Role of Biosimilars: Advancing Access, Financial Health, and System Sustainability
March 11th 2024Kashyap Patel, MD, CEO of Carolina Blood and Cancer Care, a member of the Community Oncology Alliance, and member of The Center for Biosimilars® Advisory Board, glances back at the development of the biosimilar industry and the last 5 years of progress.